TNG:EPA
Transgene SA
0,71 €
arrow_downward
-1,25%(-0,0090) 1 d.
1. okt., 15:46:10 GMT+2 · EUR
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: TNG…
Atvērt
0,72 €
Augsta
0,72 €
Zema
0,71 €
Tirgus kapitalizācija
199,16 milj.
Vid. apjoms
158,58 tūkst.
Apjoms
35,13 tūkst.
Augstākā 52 ned.
1,50 €
Zemākā 52 ned.
0,70 €
Peļņa uz vienu akciju
-0,17 €
Apgrozībā esošās akcijas
278,56 milj.
Darbinieku skaits
145
Atvērt
0,72 €
Augsta
0,72 €
Zema
0,71 €
Tirgus kapitalizācija
199,16 milj.
Vid. apjoms
158,58 tūkst.
Apjoms
35,13 tūkst.
Augstākā 52 ned.
1,50 €
Zemākā 52 ned.
0,70 €
Peļņa uz vienu akciju
-0,17 €
Apgrozībā esošās akcijas
278,56 milj.
Darbinieku skaits
145
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
PR Newswire
·
pirms 37 minūtēm
FF EAI Robotics Ecosystem Inc. (Nasdaq: FFR) and Faraday Future Intelligent Electric Inc. (FFAI) Jointly Address Key Investor Questions Regarding the Proposed Acquisition of FFAI's Robotics Business
CNBC
·
pirms 1 stundas
The Dow's rough month, Micron's revenue surge, Google launches Gemini 4 and more in Morning Squawk
markets.businessinsider.com
·
pirms 52 minūtēm
Primech Holdings (Nasdaq: PMEC) Unveils Primech Vision, Integrating a Multi-Robot Facility Fleet and Workforce on One Platform; Live Customer Demonstrations Begin October 2026
Yahoo Finance
·
pirms 4 stundām
S&P 500 alarm bells are starting to go off
Profils
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Par “Transgene SA”
Ģenerāldirektors-
Darbinieki145
Dibināšanas datumsdec. 1979
Galvenais birojs-
Sektors-
Tīmekļa vietnetransgene.com